

FIRST REGULAR SESSION

SENATE BILL NO. 614

102ND GENERAL ASSEMBLY

INTRODUCED BY SENATOR THOMPSON REHDER.

2354S.01I

KRISTINA MARTIN, Secretary

AN ACT

To amend chapter 192, RSMo, by adding thereto one new section relating to alternative therapies.

Be it enacted by the General Assembly of the State of Missouri, as follows:

Section A. Chapter 192, RSMo, is amended by adding thereto
2 one new section, to be known as section 192.950, to read as
3 follows:

192.950. 1. Notwithstanding the provisions of chapter
2 195 or 579 to the contrary, the department of health and
3 senior services, in collaboration with a hospital operated
4 by an institution of higher education in this state and with
5 a hospital or medical center operated by the U.S. Department
6 of Veterans Affairs located in this state, shall conduct a
7 study on the efficacy of using alternative medicine and
8 therapies, including, but not limited to, the use of 3, 4-
9 methylenedioxymethamphetamine (MDMA), psilocybin, and
10 ketamine, in the treatment of patients who suffer from
11 posttraumatic stress disorder, treatment-resistant
12 depression, substance abuse disorders, or who require end-of-
13 life care.

2. In conducting this study, the department, in
14 collaboration with the hospitals described in subsection 1
15 of this section and subject to appropriations, shall:

(1) Perform a clinical trial on the therapeutic
16 efficacy of using psilocybin in the treatment of
17 posttraumatic stress disorder, treatment-resistant
18
19

20 depression, substance abuse disorders, or patients who
21 require end-of-life care; and

22 (2) Review current literature regarding:

23 (a) The safety and efficacy of MDMA, psilocybin, and
24 ketamine in the treatment of patients who suffer from
25 posttraumatic stress disorder, treatment-resistant
26 depression, substance abuse disorders, or who require end-of-
27 life care; and

28 (b) The access that patients have to MDMA, psilocybin,
29 and ketamine for such treatment.

30 (3) The department shall prepare and submit to the
31 governor, lieutenant governor, and the general assembly the
32 following:

33 (a) Quarterly reports on the progress of the study; and

34 (b) A written report, submitted one year following the
35 commencement of the study, containing the results of the
36 study and any recommendations for legislative or regulatory
37 action.

38 3. The department shall maintain the confidentiality
39 of any personally identifiable protected information
40 collected during the clinical trial under this section.

41 4. Notwithstanding any other provision of law to the
42 contrary, the department, any health care providers, and any
43 other person involved in the clinical trial under this
44 section shall not be subject to criminal or civil liability
45 or sanction under the laws of this state for participating
46 in the trial, except in cases of gross negligence or willful
47 misconduct. No health care provider shall be faced with
48 discipline against his or her professional license for
49 participation in the trial.

✓